Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder

NCT04567524 is registered in ClinicalTrials.gov with Lyndra Inc. as lead sponsor.

NCT NCT04567524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04567524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder
Lead sponsor
Lyndra Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2020
Completion date
December 22, 2020
Enrollment
34 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia schizoaffective